Skip to main content
. Author manuscript; available in PMC: 2014 Feb 10.
Published in final edited form as: Sci Transl Med. 2012 Feb 29;4(123):123ra25. doi: 10.1126/scitranslmed.3003165

Figure 3. CD4 T cells from HIV-infected subjects mediate viral suppression.

Figure 3

Functional assays were performed to assess the ability of CD4 T cells from HIV-infected subjects to directly exhibit an antiviral effect. (A) Representative example of the results of one single-cycle macrophage inhibition assay; CD4 T cell effector cells were tested for their ability to reduce the number of macrophages infected with a ZsGreen reporter HIV at various effector to target (E:T) ratios. Percentages represent the number of HIV+ macrophages remaining at the end of the assay period. (B) CD4 T cells from a subset of the cohort of subjects analyzed longitudinally (n=9) were assessed for suppressive capacity in the single-cycle inhibition assay. Results are expressed as percentage of HIV+ autologous macrophages remaining and have been normalized to the respective maximum for each set of conditions. (C) CD4 T cells from a chronically HIV-infected patient were used as effectors in the single-cycle macrophage inhibition assay ex vivo or following non-specific (CD3.8) or Gag-specific expansion. (D) CD4 T cell clones were generated from the same chronically infected patient and assessed for their ability to inhibit viral replication in a standard 7 day viral inhibition assay using infected HLA-DR matched H9 cells as targets.